AHMEDABAD, India, February 23, 2015 /PRNewswire/ -- ntas becomes the first Indian company to launch a biosimilar in highly regulated markets like EU, US and Japan. The company today announced that they have launched their first biosimilar, filgrastim, in Europe, through their wholly-owned subsidiary Accord Healthcare. The product has recently been introduced under the brand Accofil® and has already won two prestigious tenders, in Netherlands and UK respectively. In addition, Intas is also the only company from India to have two of its products, filgrastim and peg-filgrastim filed for registration in the US, through its collaboration partner.
Accofil® is a biosimilar product of Neupogen® (filgrastim) and will offer patients cost effective therapy that is comparable in quality, safety and efficacy. Accofil® is indicated for the treatment of reduction in the duration of neutropenia and the incidence of febrile neutropenia, mobilization of peripheral blood progenitor cells, severe congenital, cyclic, or idiopathic neutropenia and persistent neutropenia in patients with advanced HIV infection.
Mr. Binish Chudgar, Vice-Chairman of the company, said, "The launch of our filgrastim in Europe is another demonstration of our commitment to global healthcare at affordable prices. Accofil® (filgrastim), which was developed at our own laboratories and manufactured at our own cGMP approved site in Ahmedabad, showcases our expertise in biopharmaceutical development and its manufacture. This is only the first of many biological products that we will launch in EU and other regulated markets over the next few years."
Intas is one of the pioneers and market leaders of biosimilars in India, having launched its first product in the domestic market in 2004. The company has eight biosimilar products in the market, including one monoclonal antibody MABTAS (rituximab), the largest indigenously development portfolio of biosimilar products. The company also has one of the richest pipeline of future products, that will enable it to continue to provide cost effective biosimilar alternates to imported and expensive biologic therapies, for the Indian population. Intas is the first company in India to have its biologics manufacturing facility accredited by the European Health Authority.
Intas Pharmaceuticals Limited is a leading vertically integrated Indian pharmaceutical company committed on delivering affordable and innovative pharmaceutical solutions. Its operations range from API to formulation development to large-scale commercial manufacturing to cater to global requirements. In the domestic market, Intas has a leading presence in chronic therapeutic segments and is currently ranked as the 12th largest company (As per IMS India December, 2014 MAT figures). Intas also has extensive presence in more than 70 countries worldwide with robust sales, marketing and distribution infrastructure in highly regulated markets like North America, Europe, South Africa, Australia and New Zealand etc. For the financial year ending March 2015, Intas group has recorded turnover of about Rs. 5200 cr. at 27% CAGR over the last 5 years.
For more information, visit: www.intaspharma.com
Sr. Manager - Corporate Affairs
One Advertising & Communications Ltd.
SOURCE Intas Pharmaceuticals Limited
To read more Press Release articles, click here.